STERIS plc (STE)
Equipo y servicios de salud
Global provider of infection prevention products and services organized into three segments — Healthcare, Applied Sterilization Technologies and Life Sciences — with low double-digit organic growth, expanding margins and a return on capital hovering around the 10% bar, depressed by acquisition goodwill. Trades near the top of its historical multiple band, with a limited margin of safety.
- Price
- $235.57
- Intrinsic value (5y, base)
- $352
- Total annual return (5y)
- 9.5%
- Status (nominal)
- Fairly valued
- Margin of safety
- +21%
The essentials
- Consolidated organic growth of 8.7% in fiscal 2026 (7.3% at constant currency), with all three segments growing between 8.5% and 9.6%.
- AST, the highest-margin segment (~46% of segment revenue), operates with a regulatory and single-source-material moat (cobalt-60, ethylene oxide).
- Fiscal 2027 guidance (revenue +7-8% as reported, adjusted EPS US$11.10-11.30) anchors the first projection year.
Intrinsic value — two valuation methods
Total return at 5 years: 9.5%/year = 8.4% appreciation + 1.1% dividend. The target price ($352) is ex-dividend; the $16 in dividends collected over 5 years are added separately.
By both methods, the value today (DCF $263 · Multiples $296) exceeds the market price ($236).
Pillars of the analysis
The verdict — today vs 5 years
Today — fairly valued: at $236 trades ~20.5% below its value discounted to today (~$296); the discount is positive but does not reach the margin of safety we require (≥38%).
At 5 years — En valor: the target price ($352) plus dividends yield between the 4% floor and the 10% average return — a reasonable return, though without the margin of a great investment.
The bridge: the return at 5 years exceeds the risk-free rate (4.5%) — but the discount does not reach the required margin of safety (≥38%). To require a 15% annual return, it would need to be bought at ~$185.
Thesis
The business
A provider of infection prevention products and services organized into three segments of distinct nature — Healthcare, AST and Life Sciences — each with its own set of competitors and drivers. Consolidated organic growth for fiscal 2026 was 8.7% (7.3% at constant currency), with all three segments growing between 8.5% and 9.6%. Return on invested capital hovers around the 10% bar, pushed down by the goodwill and intangibles accumulated from acquisitions (including Cantel Medical), not by operating weakness in the underlying business.
The valuation
Valued as a sum of the parts by segment, each with its own multiple derived from the med-tech band (16x-22x on EBIT): Healthcare at 19x, AST at 21x (the highest-margin segment and the most defensible moat) and Life Sciences at 17x. The blended multiple runs around 21× on consolidated EBIT, and the 5-year value in the base case is $352 per share versus the current price — a +10% annual return before dividends.
The margin of safety
It trades close to intrinsic value, far from the required margin of safety. At the method's risk-free rate with floor, the current price implies a Fairly valued return. The company's own guidance for fiscal 2027 (revenue +7-8% as reported, adjusted EPS between US$11.10 and US$11.30) anchors the first projection year, in line with the recent organic trajectory.
What to watch
The central disconfirmer is regulatory: a tougher restriction on ethylene oxide in the United States would directly hit AST, the highest-margin segment. It is also worth tracking the pace of Healthcare's margin expansion (which compressed slightly in fiscal 2026) and the execution of the new restructuring plan announced in August 2026 (an estimated US$55-70 million through fiscal 2030 for a center of excellence in North Carolina).
Educational / informational. Does not constitute investment advice.